Trial · NCT06049186
CRD vs. Met in Patients With Obese PCOS Infertility
NCT06049186, Not applicable, Unknown, Shanghai First Maternity and Infant Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CRD vs. Met in Patients With Obese PCOS Infertility. Trials, record NCT06049186. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06049186
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CRD vs. Met in Patients With Obese PCOS Infertility
- NCT number
- NCT06049186
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 406 participants, estimated
- Lead sponsor
- Shanghai First Maternity and Infant Hospital
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- CRD, Metformin
- First posted
- 2023-09-22
- Last updated
- 2023-09-22
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Live birth during the period of ovulation induction | 18 months | Live birth will be defined as the delivery of one or more living infants (≥22 week's gestation or birth weight more than 500g). The outcome could be assessed by clinical data and clinical diagnosis. |
| Secondary | Fasting blood glucose (FBG) | Baseline period and 3 months | A laboratory test that determines the level of glucose in the blood after an overnight fast, used especially to diagnose diabetes and prediabetes. The normal interval is 3.9-6.1mmol/L. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Fasting insulin (FINS) | Baseline period and 3 months | The level of insulin in the blood during fasting (usually in the morning when fasting). The normal interval is 5\~20 μIU. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Oral glucose tolerance test (OGTT) | Baseline period and 3 months | An oral glucose tolerance test (OGTT) is a diagnostic tool used to evaluate how an individual's body metabolizes sugar. Often used to diagnose diabetic conditions, an oral glucose tolerance test requires minimal preparatory measures and may be safely administered during pregnancy. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Insulin release test (IRT) | Baseline period and 3 months | Quantitative oral glucose during fasting increases blood glucose and stimulates pancreatic β cells to release insulin. By measuring plasma insulin levels during fasting and 0.5h, 1h, 2h, and 3h after taking sugar, we can understand the secretion and reserve function of pancreatic β cells, which is also helpful for the classification of diabetes mellitus and guide treatment. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Blood lipid | Baseline period and 3 months | Lipid related indicators include cholesterol, triglycerides. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Kidney function index | Baseline period and 3 months | Blood tests that are included in the kidney function test include measuring for creatinine and blood urea nitrogen (BUN). The outcome could be assessed by clinical data and clinical test. |
| Secondary | Liver function index | Baseline period and 3 months | Liver function index includes alanine aminotransferase (ALT), alkaline phosphatase (ALP) . The outcome could be assessed by clinical data and clinical test. |
| Secondary | Free testosterone (FT) | Baseline period and 3 months | The average serum testosterone concentration is 0.43ng/ml, the high limit is 0.68ng/ml, if more than 0.7ng/m1 (equal to 2.44nmol/L), it is called hypertestosterone, or hyperandrogenemia. The outcome could be assessed by clinical data and clinical test. |
| Secondary | Total testosterone (TT) | Baseline period and 3 months | The normal range of female testosterone is 0.1-0.75ng /ml, testosterone is the main sex hormone of the human body, men and women have secretion, male testosterone secretion is 20-30 times the amount of female testosterone secretion, it is very important to maintain the second sexual characteristics, bone and muscle strength. The outcome could be assessed by clinical data and clinical test. |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06049186
GET https://conductscience.org/api/trials/v1/NCT06049186/registered?page=2